

Technology Advisory Committee D Interests Register

Topic: Dabrafenib with trametinib for treating advanced BRAF V600 mutation-positive non-small-cell lung cancer [ID3851]

Publication Date: 14/06/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Chris Parker	Committee member	Non-financial professional	Professor Parker is the co-chief investigator of a trial of PSMA lutetium for prostate cancer sponsored by the MRC but funded by Novartis.	N/A	23.01.2023	N/A	It was agreed that his declaration would not prevent Professor Parker from participating in discussions on this appraisal
Professor David Meads	Committee member	Non-financial professional	University of Leeds has received funding from BMS for research in an unrelated area.	N/A	20.01.2023	N/A	It was agreed he would verbally declare and participate
Dr Robert Hodgson & Professor Sofia Dias	Committee members	Non-financial professional	Committee members Dr Hodgson & Professor Dias were part of the EAG for this appraisal	N/A	RH 26.01.2023 SD 23.01.2023	N/A	As a direct conflict Dr Hodgson & Professor Dias did not participate on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Alastair Greystoke	Clinical expert	Financial	Dr Greystoke has received consultancy and speakers' fees from Novartis in relation to the management of NSCLC; and not related to the subject of this appraisal	N/A	07.07.2023	N/A	It was agreed that his declaration would not prevent Dr Greystoke from providing expert advice to the committee.

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.